CHMP gives Sanofi's Lantus green light in over twos
This article was originally published in Scrip
The EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending Sanofi's Lantus (insulin glargine) for the treatment of diabetes mellitus in patients over two years old, extending the drug's label. Lantus was previously approved in patients over six.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.